Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 2.04  0.09  4.23%   
About 65% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over two months ago at simplywall.st         
When Can We Expect A Profit From Akebia Therapeutics, Inc.?
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo for Patients on Dialysis
Yahoo News
over three months ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over three months ago at finance.yahoo.com         
Is Entera Bio Outperforming Other Medical Stocks This Year?
Yahoo News
over three months ago at zacks.com         
Acquisition by Snow Ellen of 560000 shares of Akebia Ther at 1.67 subject to Rule 16b-3
zacks News
over three months ago at zacks.com         
Heres Why You Should Consider Buying Akebia Stock
zacks News
over three months ago at zacks.com         
5 Small Drug Stocks to Buy as Innovation Reaches Peak
zacks News
over three months ago at finance.yahoo.com         
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. This Year?
Yahoo News
over three months ago at news.google.com         
Vanguard Group Inc. Grows Stock Position in Akebia Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Akebia Therapeutics, Inc. Just Reported And Analysts Have Been Lifting Their Price Targets
Yahoo News
over three months ago at zacks.com         
Akebia Therapeutics Reports Q2 Loss, Lags Revenue Estimates
zacks News
over three months ago at seekingalpha.com         
Akebia GAAP EPS of -0.04, revenue of 43.67M
seekingalpha News
over three months ago at finance.yahoo.com         
Akebia Therapeutics Q2 Earnings Snapshot
Yahoo News
over three months ago at gurufocus.com         
Akebia Therapeutics Inc Q2 2024 Earnings EPS Misses, Revenue Falls Short at 43.6 Million
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo for Patients on Dialysis
10/07/2024
2
CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
10/10/2024
3
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo for Patients on Dialysis
10/22/2024
4
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
11/01/2024
5
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
11/05/2024
6
Akebia Q3 2024 Earnings Preview
11/06/2024
7
Akebia GAAP EPS of -0.10, revenue of 37.4M
11/07/2024
8
Akebia Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Revenue Challenges ...
11/08/2024
9
Q3 2024 Earnings Hold Akebia Therapeutics - Seeking Alpha
11/20/2024
10
Akebia Therapeutics, Inc. Sees Large Decline in Short Interest
12/02/2024

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stocks Directory
Find actively traded stocks across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance